Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Anticipated To Witness Robust Growth, Surpassing 35.93 Billion By 2029

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Current Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size and Its Estimated Growth Rate?
The market size for treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) has witnessed considerable expansion in the recent past. The market is projected to grow from $10.36 billion in 2024 to $13.32 billion in 2025, representing a compound annual growth rate (CAGR) of 28.5%. This impressive growth during the historical period is owed to factors such as an increased incidence of transthyretin amyloid cardiomyopathy, a growing prevalence of transthyretin amyloidosis in the elderly population, heightened awareness among healare professionals and patients, as well as the overall advancement and enhancement of healare services.

The market for treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) is projected to witness substantial expansion in the coming years, growing to $35.93 billion by 2029 with a compound annual growth rate (CAGR) of 28.2%. This growth during the projected period can be credited to factors such as the rising prevalence of transthyretin amyloidosis, increased diagnosis of neuropathic conditions, an aging population demographic, a surge in the demand for specific drugs to manage the rare disorder's symptoms, and heightened healare demand. Major trends for the forecast period encompass novel diagnostic technologies, the invention of advanced management techniques for therapy, innovative and targeted treatments for transthyretin amyloidosis, progress in diagnostic procedures, and cardiac MRI techniques.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304

How Are Emerging Segments Shaping the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Landscape?
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented -

1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp

Which Growth Factors Are Influencing Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Expansion?
An increase in chronic disease instances is anticipated to augment the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market's expansion. Chronic diseases, which are persistent, long-term conditions that progress gradually and often necessitate ongoing medical attention. An aging population, sedentary lifestyles, unhealthy habits, a surge in obesity, and contact with environmental pollutants are all factors contributing to the increased prevalence of these diseases. The transthyretin amyloid cardiomyopathy therapy aids in transthyretin stabilization, reduction of amyloid accumulation, improvement of heart functions, and symptom relief to better handle related chronic conditions. For example, the World Health Organization, a Swiss-based specialized agency of the United Nations, reported 41 million deaths in September 2023, accounting for 74% of fatalities caused by non-communicable diseases or chronic illnesses. There were 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes worldwide. Thus, the growing prevalence of chronic diseases is propelling the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market forward.

Who Are the Dominant Players Across Different Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Segments?
Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG

What Trends Are Driving Growth in The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Leading companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are concentrating their efforts on creating breakthrough treatments for ATTR-CM, which include orally delivered medication designed to either stabilize transthyretin (TTR) proteins or lessen the accumulation of amyloid fibril in the heart. Oral prescription medication is provided by a healare professional and usually taken in the form of tablets, capsules, or liquid. For example, in November 2024, BridgeBio Pharma Inc., an American biotech firm, was granted approval by the U.S. Food and Drug Administration for their medicinal product Attruby (acoramidis) for treating adults suffering from transthyretin amyloid cardiomyopathy (ATTR-CM). It aids in stabilizing the TTR protein, leading to a decrease in cardiac-related fatalities and hospitalizations. Clinical studies revealed that the drug was well-received and provided swift benefits by tackling the underlying cause of the disease.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-global-market-report

Which Geographic Regions Are Expected to Dominate the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market in the Coming Years?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
2. What is the CAGR expected in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
3. What Are the Key Innovations Transforming the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Industry?
4. Which Region Is Leading the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.